Wild type KRAS

About

Gene context: KRAS

Biomarker Type: Wild type

Present: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab FDA
Sensitivity (+) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab FDA
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab HC
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan FDA
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan FDA
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab FDA
Sensitivity (+) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib FDA